2 Global Neuroprotection Quarterly Market Size Analysis

• 2.1 Neuroprotection Business Impact Assessment - COVID-19
  • 2.1.1 Global Neuroprotection Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Neuroprotection Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Neuroprotection Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Neuroprotection Headquarters and Area Served
• 3.3 Date of Key Players Enter into Neuroprotection Market
• 3.4 Key Players Neuroprotection Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Neuroprotection Segments, By Type

• 4.1 Introduction
  • 1.4.1 Free Anti-Inflammatory Agents
  • 1.4.2 Radical Trapping Agents (Antioxidants)
  • 1.4.3 Apoptosis Inhibitors
  • 1.4.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
  • 1.4.5 Neurotrophic Factors (NTFs)
  • 1.4.6 Stimulants
  • 1.4.7 Metal Ion Chelators
  • 1.4.8 Other Products
• 4.2 By Type, Global Neuroprotection Market Size, 2019-2021

5 Impact of Covid-19 on Neuroprotection Segments, By Application

• 5.1 Overview
  • 5.5.1 Prevention
  • 5.5.2 Treatment
• 5.2 By Application, Global Neuroprotection Market Size, 2019-2021
  • 5.2.1 By Application, Global Neuroprotection Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 F. Hoffmann-La Roche
  • 7.1.1 F. Hoffmann-La Roche Business Overview
  • 7.1.2 F. Hoffmann-La Roche Neuroprotection Quarterly Revenue, 2020
  • 7.1.3 F. Hoffmann-La Roche Neuroprotection Product Introduction
  • 7.1.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments
• 7.2 Eli Lilly and Company
  • 7.2.1 Eli Lilly and Company Business Overview
  • 7.2.2 Eli Lilly and Company Neuroprotection Quarterly Revenue, 2020
  • 7.2.3 Eli Lilly and Company Neuroprotection Product Introduction
  • 7.2.4 Eli Lilly and Company Response to COVID-19 and Related Developments
• 7.3 Daiichi Sankyo Company
  • 7.3.1 Daiichi Sankyo Company Business Overview
  • 7.3.2 Daiichi Sankyo Company Neuroprotection Quarterly Revenue, 2020
  • 7.3.3 Daiichi Sankyo Company Neuroprotection Product Introduction
  • 7.3.4 Daiichi Sankyo Company Response to COVID-19 and Related Developments
• 7.4 Allergan
  • 7.4.1 Allergan Business Overview
  • 7.4.2 Allergan Neuroprotection Quarterly Revenue, 2020
  • 7.4.3 Allergan Neuroprotection Product Introduction
  • 7.4.4 Allergan Response to COVID-19 and Related Developments
• 7.5 Novartis
  • 7.5.1 Novartis Business Overview
  • 7.5.2 Novartis Neuroprotection Quarterly Revenue, 2020
  • 7.5.3 Novartis Neuroprotection Product Introduction
  • 7.5.4 Novartis Response to COVID-19 and Related Developments
• 7.6 AstraZeneca
  • 7.6.1 AstraZeneca Business Overview
  • 7.6.2 AstraZeneca Neuroprotection Quarterly Revenue, 2020
  • 7.6.3 AstraZeneca Neuroprotection Product Introduction
  • 7.6.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.7 Dr. Reddy's Laboratories
  • 7.7.1 Dr. Reddy's Laboratories Business Overview
  • 7.7.2 Dr. Reddy's Laboratories Neuroprotection Quarterly Revenue, 2020
  • 7.7.3 Dr. Reddy's Laboratories Neuroprotection Product Introduction
  • 7.7.4 Dr. Reddy's Laboratories Response to COVID-19 and Related Developments
• 7.8 Astrocyte Pharmaceuticals
  • 7.8.1 Astrocyte Pharmaceuticals Business Overview
  • 7.8.2 Astrocyte Pharmaceuticals Neuroprotection Quarterly Revenue, 2020
  • 7.8.3 Astrocyte Pharmaceuticals Neuroprotection Product Introduction
  • 7.8.4 Astrocyte Pharmaceuticals Response to COVID-19 and Related Developments
• 7.9 Teva Pharmaceutical Industries
  • 7.9.1 Teva Pharmaceutical Industries Business Overview
  • 7.9.2 Teva Pharmaceutical Industries Neuroprotection Quarterly Revenue, 2020
  • 7.9.3 Teva Pharmaceutical Industries Neuroprotection Product Introduction
  • 7.9.4 Teva Pharmaceutical Industries Response to COVID-19 and Related Developments
• 7.10 Biogen
  • 7.10.1 Biogen Business Overview
  • 7.10.2 Biogen Neuroprotection Quarterly Revenue, 2020
  • 7.10.3 Biogen Neuroprotection Product Introduction
  • 7.10.4 Biogen Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US

This report covers market size and forecasts of Neuroprotection, including the following market information:
Global Neuroprotection Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players
Major competitors identified in this market include F. Hoffmann-La Roche, Eli Lilly and Company, Daiichi Sankyo Company, Allergan, Novartis, AstraZeneca, Dr. Reddy's Laboratories, Astrocyte Pharmaceuticals, Teva Pharmaceutical Industries, Biogen, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Free Anti-Inflammatory Agents
Radical Trapping Agents (Antioxidants)
Apoptosis Inhibitors
Glutamate Antagonists (Anti-Excitotoxic Agents)
Neurotrophic Factors (NTFs)
Stimulants
Metal Ion Chelators
Other Products

Based on the Application:
Prevention
Treatment